Phaseline

Companies › Wayshine Biopharm

Wayshine Biopharm: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WSD0922-FU
EGFR-TKI (third-generation)
EGFRPhase 2Non Small Cell Lung Cancer; EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer (NSCLC)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06631989WSD0922-FUPhase 1EGFR Mutation Positive Advanced Non-Small Cell Lung CancerOncologyJun 2027
NCT06868485WSD0922-FUPhase 2Non Small Cell Lung CancerOncologySep 2027
NCT07206498WSD0922-FUPhase 1Non Small Cell Lung Cancer (NSCLC)OncologyOct 2028

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Black Diamond Therapeutics Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical Jiangsu Alphamab Biopharmaceuticals Rakuten Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.